Avalo Therapeutics, Inc. Research And Development Expense

• Avalo Therapeutics, Inc. showed an increase of +32.3% in Research And Development Expense from 2017 to 2018.
• This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2019.
• XBRL data for this metric is available from 2013 to 2018 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2014: $2.75 million | Q2 2014: $2.86 million | Q3 2014: $4.37 million | Q4 2014: $2.26 million | Q1 2015: $1.72 million | Q2 2015: $1.88 million | Q3 2015: $1.24 million | Q4 2015: $1.75 million | Q1 2016: $2.29 million | Q2 2016: $2.50 million | Q3 2016: $4.58 million | Q4 2016: $773.0 thousand | Q1 2017: $953.1 thousand | Q2 2017: $493.6 thousand | Q3 2017: $965.0 thousand | Q4 2017: $1.96 million | Q1 2018: $1.65 million | Q2 2018: $1.08 million | Q1 2019: $3.40 million.
• Over the full 6 years of available data (2013 to 2018), Avalo Therapeutics, Inc.'s Research And Development Expense has declined by 35.1%.
• Historical annual values: Fiscal year 2018: $5.79 million | Fiscal year 2017: $4.37 million | Fiscal year 2016: $10.15 million | Fiscal year 2015: $6.59 million | Fiscal year 2014: $12.24 million | Fiscal year 2013: $8.91 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026